The drug pevonedistat has shown a lot of success in many phase 1 clinical trials. Is it possible that it will exhibit the same outcome in combating mesothelioma? Researchers anticipate that it could.

Recruiting Pleural and Peritoneal Patients

A clinical trial sponsored by the Memorial Sloan Kettering Cancer Center is testing the use of the drug pevonedistat in treating mesothelioma patients. This trial is currently recruiting patients that have been diagnosed with pleural or peritoneal mesothelioma.

Drugs Used in This Trial
  • Pevonedistat – is an enzyme that inhibits NEDD8. NEDD8 is a protein that helps with repairing damaged DNA. It works by restraining tumor cell proliferation and survival.
  • Pemetrexed – this agent is used in combination with other chemotherapy drugs. It helps block substances in the body that may aid in multiplying cancer cells.
  • Cisplatin – a common drug used in chemotherapy for mesothelioma. It works by slowing down and stopping the growth of cancer cells.

In collaboration with the M.D. Anderson Cancer Center, the Memorial Sloan Kettering Cancer Center hopes that pevonedistat can be a beneficial and safe treatment option for patients that are combating mesothelioma.

Get Help Enrolling in This Trial

The lack of treatment options for mesothelioma relative to those for other cancers make clinical trials an invaluable source of treatment. One of the benefits of this trial is that it is accepting patients that have all types of mesothelioma cells.

Reasons to get involved in this trial include:
  • Receiving proven life-extending treatment
  • Get treated at a top ranking medical center
  • Pevonedistat has shown a lot of success in many phase 1 clinical trials




What Can a Participant Expect?

The good thing about this clinical trial is that there isn’t a placebo group. Every participant will receive some form of treatment for their disease.

This study anticipates to recruit about 42 participants. These individuals will be divided into two groups.

  • 1
    Group 1: this group will be given pevonedistat as a single agent. The participants will be testing the efficacy of the NEDD8 inhibitor and how effective it is in treating mesothelioma patients that have a NF2 mutation.
  • 2
    Group 2: this group will receive pevonedistat combined with standard chemotherapy. The chemotherapy drugs that this cohort will be given are pemetrexed and cisplatin.
Patient Inclusion

To be able to participate in this clinical trial, a patient must
  • Have a confirmed diagnosis of malignant pleural or peritoneal mesothelioma.
  • Not be able to participate in surgery.
  • Be chemo-naive or have tried first-line chemotherapy for mesothelioma.

Unlike many clinical trials that only accept patients that have a specific type of mesothelioma, this clinical trial is open to individuals that have all cell types. Participants can have epithelioid, sarcomatoid or biphasic histology.

Patient Ineligibility

A patient cannot participate in this trial if they are
  • Currently receiving radiation treatment. A participant must have had their last radiation treatment 2 weeks prior to entering the study.
  • Recovering from any type of major surgery.
  • Having other uncontrolled medical conditions.

Unfortunately, since clinical trials are considered experimental, not all patients can participate in them. Factors such as a person’s disease or staging can play a factor in determining what is safe for them. Be sure to consult with your doctor about other ineligibility criteria.

What is a NF2 Mutant?

In order to qualify for group 1 of this study, a patient must have an NF2 mutation. NF2 is a gene that instructs a protein called schwannomin to develop. It helps with suppressing tumors and preventing cells to grow and divide uncontrollably.

This protein helps cells
  • Keep their shape
  • Grow
  • Attach to each other

Researchers believe that many mesothelioma cases consist of an individual that has either lost or has an inactive NF2 gene. This mutation is associated with how quickly a person’s tumor will either grow or spread. It also reflects how likely a tumor may or may not respond to treatment.

Getting to Know the Memorial Sloan Kettering Cancer Center

One of the best things about this clinical trial is that it is occurring at several of the Memorial Sloan Kettering locations. Each facility focuses on making sure a patient’s care needs are met – no matter how rare their disease is.

“Because we know we’re not just treating your cancer — we’re treating you.”
– Memorial Sloan Kettering’s motto.

Location

The Memorial Sloan Kettering Cancer Center has facilities located in New York and New Jersey. It is considered one of the top cancer centers in the United States. In fact, the U.S. News & World Report ranked it as number 2 on the Top 5 Cancer Centers list of 2017 – 2018.

This cancer center is home to mesothelioma experts that are specialized in treating peritoneal and pleural mesothelioma. Their goal is to create a personal team that creates a plan that is individualized to both a patient and their disease.

Meet Majorie G. Zauderer

Marjorie G. ZaudererLead investigator of this clinical trial is Majorie G. Zauderer. She is a medical oncologist that specializes in treating patients that have lung cancer and mesothelioma.

 

“I am conducting research to test new drugs for the treatment of non-small cell lung cancer and mesothelioma as well as to optimize the care of patients with multiple primary lung cancers,” Majorie states on the Memorial Sloan Kettering Cancer Center website.

Majorie has a huge interest in people who have inherited a predisposition to cancer. She is also passionate about investigating inherited BAP1 mutations in patients that have malignant pleural mesothelioma.

Is This Clinical Trial for You?

If you feel like this clinical trial may be a perfect match for you, please feel free to contact us for more information. Nurse Jenna is available to answer any medical questions that you may have.

You can reach Jenna by calling 888-385-2024 extension 102. You may also contact her by email at jenna@mesotheliomaguide.com.

Unfortunately, 20 to 30% of mesothelioma patients will not receive any type of treatment. Don’t let yourself become a part of this statistic. Get connected to a clinical trial today.